No quarterly revenue total was found in Minerva Neurosciences, Inc.'s SEC filings.
Minerva Neurosciences, Inc. (NERV) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
$17.47M
+636.0% vs year-ago quarter
Operating cash flow
$-13.34M
-553.5% vs year-ago quarter
Free cash flow
—
EPS
$-0.14
+67.4% vs year-ago quarter
Dividend per share
None
Shares outstanding
47.75M
+582.8% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NERV (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- MA
- Headquarters
- Burlington, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1598646
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$10.6M | -$16.7M | -$5.0M | -$2.8M | -$3.4M |
| Net income | $17.5M | -$125.4M | -$283.7M | -$2.7M | -$3.3M |
| Diluted EPS | -$0.14 | -$2.86 | -$25.54 | -$0.36 | -$0.43 |
| Operating cash flow | -$13.3M | -$5.4M | -$4.5M | -$2.9M | -$2.0M |
| Total assets | $95.1M | $94.0M | $98.0M | $28.1M | $30.4M |
| Total liabilities | $296.6M | $343.1M | $233.8M | $62.7M | $62.5M |
| Stockholders' equity | -$213.3M | -$254.0M | -$140.7M | -$34.6M | -$32.1M |
| Cash and investments | $75.3M | $78.1M | $82.3M | $12.3M | $15.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 6, 2026 | Nov 6, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 12, 2026 | Aug 10, 2026 |
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 7, 2026 | Aug 7, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change, Shareholder vote results
|
Jun 4, 2026 | Jun 3, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
May 27, 2026 | May 27, 2026 |
All 646 Minerva Neurosciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.